GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Other Gross PPE

VRCDF (Verici Dx) Other Gross PPE : $1.07 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Other Gross PPE?

Verici Dx's Other Gross PPE for the quarter that ended in Jun. 2024 was $1.07 Mil.

Verici Dx's quarterly Other Gross PPE declined from Jun. 2023 ($1.64 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Jun. 2024 ($1.07 Mil).

Verici Dx Other Gross PPE Historical Data

The historical data trend for Verici Dx's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Other Gross PPE Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Other Gross PPE
- - - -

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Gross PPE Get a 7-Day Free Trial 1.31 - 1.64 - 1.07

Verici Dx Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Verici Dx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Other Gross PPE
Comparable Companies
LSE:GENI LSE:PRM LSE:LLAI LSE:GDR LSE:ABDX LSE:AGL TMO DHR XSWX:LONN A IQV IDXX MTD WAT SHSE:603259 ILMN NTRA LH ICLR DGX
Traded in Other Exchanges
VRCI:UK
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Website
https://www.vericidx.com
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines